|
|
|
|
|
|
|
|
|
CGTs For HIV Suppression With Addimmune's Dr. Marcus Conant
|
Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV. He spent his career on the front lines of research and remains an advocate for the HIV patient. On Cell & Gene: The Podcast, Dr. Conant talks about Addimmune’s lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape. Listen now!
|
|
|
|
|
|
|
Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.
|
|
|
|
|
To continue the momentum created by new discoveries and treatments for cancer patients, drug developers need a strong and focused corporate culture, employees willing to challenge established norms, and a system for prioritizing development candidates guided by science and patient needs.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Understanding The 5 Elements Of cGMP
|
cGMP outlines safety procedures for every basic part of production – defining how to keep products safe, operate machinery properly, validate processes, and maintain consistent procedures.
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER
|
|
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
|
|
|
| Connect With Life Science Leader: |
|
|
|
|
